SCYNEXIS, Inc. (NASDAQ:SCYX) Shares Acquired by AMH Equity Ltd

AMH Equity Ltd lifted its holdings in shares of SCYNEXIS, Inc. (NASDAQ:SCYX) by 134.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 550,400 shares of the company’s stock after acquiring an additional 315,612 shares during the period. SCYNEXIS accounts for approximately 1.1% of AMH Equity Ltd’s portfolio, making the stock its 18th biggest holding. AMH Equity Ltd’s holdings in SCYNEXIS were worth $1,227,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Acadian Asset Management LLC bought a new stake in SCYNEXIS during the third quarter worth approximately $673,000. Kingdon Capital Management L.L.C. raised its holdings in SCYNEXIS by 8.7% during the third quarter. Kingdon Capital Management L.L.C. now owns 1,877,148 shares of the company’s stock worth $4,280,000 after purchasing an additional 150,157 shares in the last quarter. D.A. Davidson & CO. raised its holdings in SCYNEXIS by 34.0% during the third quarter. D.A. Davidson & CO. now owns 486,326 shares of the company’s stock worth $1,109,000 after purchasing an additional 123,325 shares in the last quarter. O Shaughnessy Asset Management LLC bought a new stake in SCYNEXIS during the third quarter worth approximately $94,000. Finally, Wealth Effects LLC raised its holdings in SCYNEXIS by 26.3% during the fourth quarter. Wealth Effects LLC now owns 117,500 shares of the company’s stock worth $262,000 after purchasing an additional 24,500 shares in the last quarter. 54.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SCYX has been the topic of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of SCYNEXIS in a report on Monday, April 1st. StockNews.com cut SCYNEXIS from a “buy” rating to a “hold” rating in a report on Monday, March 18th.

SCYNEXIS Price Performance

NASDAQ SCYX opened at $1.54 on Friday. The stock has a market capitalization of $58.14 million, a P/E ratio of 1.17 and a beta of 1.57. SCYNEXIS, Inc. has a 1 year low of $1.35 and a 1 year high of $3.87. The business’s fifty day moving average is $1.56 and its two-hundred day moving average is $1.74. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.26 and a current ratio of 6.26.

SCYNEXIS Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.